These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1570 related articles for article (PubMed ID: 29937183)
1. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183 [TBL] [Abstract][Full Text] [Related]
2. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994 [TBL] [Abstract][Full Text] [Related]
3. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246 [TBL] [Abstract][Full Text] [Related]
4. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344 [TBL] [Abstract][Full Text] [Related]
5. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732 [TBL] [Abstract][Full Text] [Related]
6. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910 [TBL] [Abstract][Full Text] [Related]
7. Mutation Status of Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662 [TBL] [Abstract][Full Text] [Related]
8. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237 [TBL] [Abstract][Full Text] [Related]
9. Genomic and prognostic heterogeneity among RAS/BRAF Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154 [TBL] [Abstract][Full Text] [Related]
10. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540 [TBL] [Abstract][Full Text] [Related]
17. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864 [TBL] [Abstract][Full Text] [Related]
18. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status. Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279 [TBL] [Abstract][Full Text] [Related]